Complying With Life Science Sterilization Control Mandates
STAFFORD, UNITED KINGDOM, July 5, 2023/EINPresswire.com/ — The traceability of pharmaceutical manufacturing processes is critical to navigating the complexity of government regulations that impact the design, development, production and distribution of medications. The recent introduction of the EudraLex Volume 4 Annex 1 guidance regarding the manufacturing of sterile medicinal products is an example of good manufacturing practices (GMPs) that help ensure quality and safety. But the challenge comes with documenting the process, as Roberto Zerbi, global life sciences business development manager at industrial technology manufacturer Watlow, explains.
The EudraLex Volume 4 Annex 1 guidance, which comes into effect in August 2023, illustrates how new regulations are introduced to grow trust in the life sciences business.
Sterilizers play a key role in producing injectable medicines like vaccines. Life science firms and the machine builders that support them must find the most efficient way to meet the data integrity principles applied to the records of each heat sterilization cycle.
Point 8.50 of the EudraLex Volume 4 Annex 1 states: “Each heat sterilization cycle should be recorded electronically or by hardcopy, using equipment with suitable accuracy and precision. The system should have safeguards and/or redundancy in its control and monitoring instrumentation to detect a cycle not conforming to the validated cycle parameter requirements and abort or fail this cycle (e.g., by the use of duplex/double probes connected to independent control and monitoring systems).”
Sterilization control challenges
When dealing with the challenges of heat and steam sterilization for monitoring and controlling activities, life sciences stakeholders and the OEMs supplying them with equipment are faced with multiple options for meeting the regulatory compliance mandate. But, there must always properly balance the trade-off between efficiency, cost and time-to-market.
The new Annex 1 changes the status quo for OEMs and potentially introduces more machine building cost, time and risk. OEMs must qualify any new device added to their equipment and minimise downtime risks, as well as ensuring staff are trained, expand their maintenance capabilities and manage delays in time-to-market due to extended testing procedures.
Changes have an impact on quality control managers too. They are confronted with thousands of pages of regulatory statutes that they need to recognise and manage, which is difficult as new regulations are published continuously. It is critical for quality managers to have access to reliable solutions to stay up-to-date and ahead of validation inspectors.
Qualification and validation
In the case of the new EudraLex regulation, the crux of the issue is the ability to document the positive completion of the sterilization process. This could be achieved through a separate monitoring system that provides the simplicity, robustness and accuracy expected by regulators. Organisations like Watlow, which designs and manufactures industrial technology for thermal applications, understand the impact of the new mandates on the sterilization process are in a solid position to meet this challenge.
In partnership with Eurotherm, Watlow has developed a paperless sterilization quality management solution that combines industry regulatory knowledge with hardware and software components. This makes it easy for OEMs to integrate the new EudraLex Volume 4 Annex 1 requirement into their production machines. The solution comprises a best-in-class sensor connected to a redundant solution, which delivers the mandatory monitoring and recording required for compliance. It then digitally feeds the control system simultaneously achieving simplicity, robustness and an extremely high level of accuracy.
Monitoring sensors are the most critical device in the sterilization process. If the sensor fails, the sterilization batch has to be put on hold. OEMs must invest in a high-quality sensor, like that from Watlow, and enable the high-availability redundant monitoring solution to provide the environmental measurements to the control system.
Compliance is key when it comes to pharmaceutical manufacturing processes, but recording and monitoring of critical process data can make life difficult for OEMs trying to keep up to date with constantly changing regulations. With the help of a reliable and robust paperless sterilization monitoring solution, OEMs can integrate the EudraLex requirements seamlessly to maintain quality and safety.
To learn more about Watlow, visit watlow.com, or to learn more about Eurotherm, visit eurotherm.com
Editor’s note: If you want to ensure you keep up to date with the latest content from Watlow, visit the website: https://www.watlow.com/news
For further information contact:
European headquarters:
Johann Lainer
Tel: +43 6244 201 29-0
E-mail: jlainer@watlow.com
Address: Watlow Plasmatech GmbH, Brennhoflehen-Kellau 156, 5431 Kuchl, Austria
US Headquarters: 12001 Lackland Rd., St. Louis, MO, 63146
Tel.: 1-(800)-928-5692
Address: 12001 Lackland Rd., St. Louis, MO, 63146
Telephone: 1+ (800) WATLOW2, 1+ (314) 878-4600
Sales Inquiries: 1-(800)-928-5692
E-Mail: watlowleads@watlowleads.com Fax: 1+ (877) 893-1005, 1+ (314) 878-6814
www: https://www.watlow.com/
LinkedIn: https://www.linkedin.com/company/watlow/
Press enquiries: Courtney Cowperthwaite or Francesca Avigo – Stone Junction Ltd
The Malthouse, Water Street, Stafford, Staffordshire, ST16 2AG
Telephone: +44 (0) 1785 225416
e-mail: courtney@stonejunction.co.uk or francesca@stonejunction.co.uk
www: http://www.wechangeminds.co.uk
Twitter: https://twitter.com/StoneJunctionPR
Facebook: http://www.facebook.com/technicalPR
LinkedIn: https://www.linkedin.com/company/stone-junction-ltd
About Watlow:
Founded in 1922, Watlow strives to be the leading provider of thermal solutions for the world’s most demanding applications. Utilizing our advanced technology, leading companies apply our thermal systems which are ideally suited for vital applications such as clean and environmentally-friendly energy systems and processes, front-end semiconductor processing and lifesaving medical and clinical equipment. Since 1922, Watlow has grown in product capability, market experience and global reach. The company holds more than 1,100 patents and employs 6,000 team members working in 12 manufacturing facilities and five advanced technology and development centers in the United States, Mexico, Europe and Asia. Watlow covers 95 countries through sales and distribution offices around the world. The company continues to grow, while the commitment remains the same – to provide its customers with superior products and services for their individual needs.
Ref: WAT082/06/23
Courtney Cowperthwaite/Francesca Avigo
Stone Junction Ltd
+44 1785 225416
courtney@stonejunction.co.uk
